Case Reports

Clinical and Translational Oncology

, Volume 12, Issue 4, pp 310-314

First online:

Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN

  • Ana CustodioAffiliated withMedical Oncology Department, Hospital Universitario Clínico San Carlos Email author 
  • , Antonio CallesAffiliated withMedical Oncology Department, Hospital Universitario Clínico San Carlos
  • , Pedro Pérez-SeguraAffiliated withMedical Oncology Department, Hospital Universitario Clínico San Carlos

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.

Keywords

Glioblastoma multiforme Recurrent disease Epidermal growth factor receptor PTEN Tyrosine kinase inhibitors